Sign up to The Irish Times Archive (1859 - 2008)My Account »
Thu 10 Oct 2009Sales of Tysabri fuel growth in Elan profits
IRISH BIOTECH group Elan reported profit after tax of $52 million in the third quarter, driven by strong growth in sales of multiple sclerosis drug Tysabri and factors associated with the recent $885 million investment by Johnson & Johnson.
Over 46,300 patients are now taking Tysabri, a 30 per cent increase on the same period last year. Sales of the drug rose 16 per cent to $191.4 million in the three months to September, accounting for two-thirds of Elan’s group revenue of $287 million.
Choose a Subscription type - required
